Immunic is a clinical-stage biopharmaceutical company developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease and psoriasis. Co.'s development programs are: the IMU-838 program, which is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase; the IMU-935 program, which is focused on an inverse agonist of RORyt, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function. The IMUX stock yearly return is shown above.
The yearly return on the IMUX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMUX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|